NasdaqGM:HROWPharmaceuticals
Is Harrow's (HROW) Expanding Ophthalmic Pipeline Strengthening Its Long-Term Market Position?
Harrow, Inc. recently reported second-quarter results, showing revenue of US$63.74 million and net income of US$5 million, alongside several business development updates including product launches and distribution alliances.
The collaboration with Apollo Care is expected to enhance the reach and prescription volumes of VEVYE, while recent acquisitions such as BYQLOVI and an ophthalmic biosimilars portfolio further expand Harrow's presence in postoperative care and retina markets.
We'll...